Chronic lymphocytic leukemia (CLL) patients diagnosed with severe acute respiratory syndrome coronavirus-2 disease (COVID-19) are at high risk of hospitalization and death independently of disease phase or treatment status. Considering these observations, we collected data from 21 CLL referral centers in Italy to better understand the attitude toward choice and management of venetoclax- based treatment during the pandemic, also in the light of ASH recommendations.

How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia

Visentin, Andrea;Quaresmini, Giulia;Sanna, Alessandro;Ferrarini, Isacco;
2022-01-01

Abstract

Chronic lymphocytic leukemia (CLL) patients diagnosed with severe acute respiratory syndrome coronavirus-2 disease (COVID-19) are at high risk of hospitalization and death independently of disease phase or treatment status. Considering these observations, we collected data from 21 CLL referral centers in Italy to better understand the attitude toward choice and management of venetoclax- based treatment during the pandemic, also in the light of ASH recommendations.
COVID-19
Chronic lymphocytic leukemia
Rituximab
venetoclax
File in questo prodotto:
File Dimensione Formato  
How COVID 19 pandemic changed our attitude to venetoclax based treatment in chronic lymphocytic leukemia.pdf

solo utenti autorizzati

Tipologia: Versione dell'editore
Licenza: Creative commons
Dimensione 966.46 kB
Formato Adobe PDF
966.46 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1081769
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 1
social impact